Research Digest

Weight fell by up to 18.8% on the highest dose versus 5.1% on placebo. Stomach side effects were common, and more people stopped the drug at the higher doses.

Weight fell by 9.6% on the highest dose versus 2.5% on placebo over 72 weeks. Stomach side effects, mostly while the dose was being increased, were the main reason people stopped.

Average weight loss was 12.1% versus 2.2% on placebo over 44 weeks, in people who count as overweight under the lower BMI thresholds used in China.

Joint response on its own was better with the combination (33.5% vs 20.4%). The headline 31.7% vs 0.8% figure combines joint response with weight loss.

30 people across three studies, none with a control group. The reviewers rate the certainty of the evidence as very low.

In healthy men, a continuous infusion stopped raising LH and FSH within five days, but 8 hours on and 16 hours off kept the response going. A small hormone study.

100 people with alcohol use disorder: no difference from placebo on the main outcome, though anger and aggression scores were lower on oxytocin.

In a 73-patient open-label trial, adding thymosin α1 to standard care improved 90-day survival without a transplant. This analysis looks at the immune changes behind it.

A secondary analysis of a 72-person trial found changes in a laboratory choice task after 16 weeks of oral semaglutide. It doesn’t report effects on depression itself.

Animal and lab work: aged human eggs also matured better in the dish. No human fertility trial has been done.